文献速递泌尿生殖介入MRUS

MRI引导聚焦超声局灶治疗中危前列腺癌:一项2年II期临床试验的最终结果

MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial.
PubMed 文献 · Radiology · 2024-01-01

这项单中心前瞻性II期试验纳入44例局限单灶中危前列腺癌患者,于2016年7月至2019年7月接受经直肠MRI引导聚焦超声局灶治疗,计划消融边缘10 mm。2年时43例中39例(91%)治疗部位无临床显著前列腺癌,36例(84%)全腺体无癌;国际勃起功能指数-15评分与国际前列腺症状评分2年随访无变化(P=.73和.39),无重大不良事件。

要点

  • 2年时91%(39/43)治疗部位无临床显著前列腺癌,84%(36/43)全腺体无癌。
  • 国际勃起功能指数-15评分与国际前列腺症状评分2年随访无显著变化(P=.73和.39)。
  • 44例中无治疗相关重大不良事件记录,1例拒绝24个月活检。

核心结论

  • 多数接受MRI引导聚焦超声治疗的中危前列腺癌患者治疗2年后活检无临床显著前列腺癌,经验证问卷评估的生活质量无显著下降。

研究设计与样本

  • 单中心前瞻性II期临床试验,纳入44例局限单灶中危前列腺癌患者(中位年龄67岁,IQR 62-70岁;36例GG 2,8例GG 3),于2016年7月至2019年7月接受经直肠MRI引导聚焦超声局灶治疗,计划消融体积尽可能包括10 mm边缘,24个月行多参数MRI及靶向和系统活检,以即刻增强图像上手动勾画无灌注体积确定消融体积,采用广义估计方程建模生活质量趋势,试验注册号NCT02968784。

诊断标准与关键数值

  • 2年时43例中39例(91%)治疗部位无临床显著前列腺癌,36例(43例中,84%)全腺体无癌。
  • 国际勃起功能指数-15评分2年随访无变化(P=.73),国际前列腺症状评分无变化(P=.39)。

临床应用与阅片要点

  • 作者结论认为多数中危前列腺癌患者接受MRI引导聚焦超声后2年活检无临床显著前列腺癌,经验证问卷评估的生活质量无显著下降。

局限性

  • 原文指出该方法的长期结局需要更多研究。
  • 1例参与者拒绝24个月活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background MRI-guided focal therapy (FT) allows for accurate targeting of localized clinically significant prostate cancer (csPCa) while preserving healthy prostate tissue, but the long-term outcomes of this approach require more study. Purpose To assess the 2-year oncological and functional outcomes of men with intermediate-risk prostate cancer (PCa) treated with targeted FT. Materials and Methods In this single-center prospective phase II trial, men with localized unifocal intermediate-risk PCa underwent transrectal MRI-guided focused ultrasound between July 2016 and July 2019. Planned ablation volumes included 10-mm margins when possible. Data regarding adverse events were collected and quality-of-life questionnaires were completed by participants at 6 weeks and at 5, 12, 18, and 24 months after treatment. Multiparametric MRI and targeted and systematic biopsies were performed at 24 months. Ablation volumes were determined by manual contouring of nonperfused volumes on immediate contrast-enhanced images. Generalized estimating equations were used to model trends in quality-of-life measures. Results Treatment was successfully completed in the 44 participants (median age, 67 years; IQR, 62-70 years; 36 patients with grade group [GG] 2; eight patients with GG 3). No major adverse events from treatment were recorded. One participant refused biopsy at 24 months. After 2 years, 39 of 43 participants (91%) had no csPCa at the treatment site and 36 of 43 (84%) had no cancer in the entire gland. No changes in International Index of Erectile Function-15 score or International Prostate Symptom Score were observed during 2-year follow-up (P = .73 and .39, respectively). Conclusion The majority of men treated with MRI-guided focused ultrasound for intermediate risk PCa had negative results for csPCa at biopsy 2 years after treatment. Additionally, there was no significant decline in quality of life per the validated questionnaires. Clinical trial registration no. NCT02968784 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Woodrum in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ghai S, Finelli A, Corr K, et al. MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial. Radiology. 2024. PMID: 38441092. doi:10.1148/radiol.231473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。